Insulin, insulin resistance and platelet function: Similarities with insulin effects on cultured vascular smooth muscle cells

Diabetologia

Volumn 41, Issue 6, 1998, Pages 609-622

  Trovati, M ^a   Anfossi, G ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Calcium; cAMP; cGMP; Insulin; Insulin resistance; Nitric oxide; Platelets; Prostacyclin; Vascular Smooth Muscle

Indexed keywords

ANGIOTENSIN; CALCIUM; CYCLIC AMP; CYCLIC NUCLEOTIDE; INSULIN; INSULIN RECEPTOR; NITRIC OXIDE; PROSTACYCLIN; VASODILATOR AGENT;

ATHEROGENESIS; CALCIUM TRANSPORT; CELL CULTURE; DIABETES MELLITUS; FIBRINOLYSIS; INSULIN RESISTANCE; INSULIN SENSITIVITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTE KINETICS; VASCULAR SMOOTH MUSCLE;

BLOOD PLATELETS; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; INSULIN; INSULIN RESISTANCE; MUSCLE, SMOOTH;

EID: 0031838104     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050958     Document Type: Review

References (190)

1. Savage PJ, Saad MF (1993) Insulin and atherosclerosis: villain, accomplice, or innocent bystander? Br Heart J 69: 473-475
2. Jarrett RJ (1994) Why insulin is not a risk factor for coronary heart disease? Diahetologia 37: 945-947
3. Fontbonne A (1994) Why can insulin levels indicate a risk for coronary heart disease? Diabetologia 37: 953-955
4. Stern MP (1994) The insulin-resistance syndrome: the controversy is dead, long live the controversy! Diabetologia 37: 956-958
5. Stout RW, Valliance-Owen W (1969) Insulin and atheroma. Lancet 2: 1078-1080
6. Ross R (1986) The pathogenesis of atherosclerosis - an update. N Engl J Med 314: 488-500
7. Niederman R, Pollard TD (1975) Human platelet myosin. II. In vitro assembly and structure of myosin filaments. J Cell Biol 67: 72-92
8. Colwell JA, Winocour PD, Lopes-Virella MF (1989) Platelet function and platelet-plasma interactions in atherosclerosis and diabetes mellitus. In: Rifkin H, Porte D (eds) Diabetes Mellitus: theory and practice. Elsevier, New York, pp 249-256
9. Kroll MH, Schafer AI (1989) Biochemical mechanisms of platelet activation. Blood 74: 1181-1195
10. Siess W (1989) Molecular mechanisms of platelet activation. Physiol Rev 69 (1): 48-178
11. Ware AJ, Coller BS (1995) Platelet morphology, biochemistry and function. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ (eds) Williams Hematology, McGraw-Hill Inc, New York, pp 1161-1201
12. Anfossi G, Trovati M (1996) Role of catecholamines in platelet function: pathophysiological and clinical significance. Eur J Clin Invest 26: 353-370
13. Ardlie NG (1982) Calcium ions, drug action, and platelet function. Pharmacol Ther 18: 249-270
14. 2 formation. J Biol Chem 266: 19232-19237
15. 2+ redistribution in activated human platelets. Biochem J 304: 993-999
16. Standley PR, Gangasani S, Prakash R, Sowers JR (1991) Human platelet calcium measurements: methodological considerations and comparisons with calcium mobilization in vascular smooth muscle cells. Am J Hypertens 4: 546-549
17. Somlyo AP, Somlyo AV (1994) Signal transduction regulation in smooth muscle. Nature (Lond) 372: 231-236
18. El-Daher SS, Eigenthaler M, Walter U et al. (1996) Distribution and activation of cAMP-and cGMP-dependent protein kinases in highly purified human platelet plasma and intracellular membranes. Thromb Haemost 76: 1063-1071
19. Lerea KM, Glomset JA (1987) Agents that elevate the concentrations of cAMP in platelets inhibit the formation of NaDodSO4-resistant complex between thrombin and 40-kDa protein. Proc Natl Acad Sci USA 84: 5620-5624
20. Watson SP, McConnell RT, Lapetina E (1984) The rapid formation of inositol phosphates in human platelets by thrombin is inhibited by prostacyclin. J Biol Chem 259: 13199-13203
21. Doni MG, Deana R. Bertoncello S, Zoccarato F, Alexandre A (1988) Forskolin and prostacyclin inhibit fluoride-induced platelet activation and protein kinase C-dependent responses. Biochem Biophys Res Commun 156: 1316-1323
22. 2+ extrusion from human platelets. Biochim Biophys Acta 1105: 19-28
23. 2+ uptake in human platelets by cAMP. Biochim Biophys Acta 1105: 29-39
24. Geiger J, Nolte C, Butt E, Sage SO, Walter U (1992) Role of cGMP and cGMP-dependent protein kinase in nitrova-sodilator inhibition of agonist-evoked calcium elevation in human platelets. Proc Natl Acad Sci USA 89: 1031-1035
25. Deana R, Ruzzene M, Doni MG, Zoccorato F, Alexandre A (1989) Cyclic GMP and nitroprusside inhibit activation of human platelets by fluoroaluminate. Biochim Biophys Acta 1014: 203-206
26. Doni MG, Deana R, Padoin E, Ruzzene M, Alexandre A (1991) Platelet activation by diacylglycerol or ionomycin is inhibited by nitroprusside. Biochim Biophys Acta 1094: 323-329
27. Cavallini L, Coassin MG, Borean A, Alexandre A (1996) Prostacyclin and sodium nitroprusside inhibit the activity of the platelet inositol 1,4,5-trisphosphate receptor and promote its phosphorylation. J Biol Chem 8: 5545-5551
28. 2+ influx in platelets: activation by thrombin and by the depletion of stores. Effect of cyclic nucleotides. Biochem J (1994) 303: 599-605
29. Kimura M, Kasker N, Aviv A (1982) Cyclic nucleotides attenuate thrombin-evoked alterations in parameters of platelet Na/H antiport. The role of cytosolic pH. J Clin Invest 89: 1121-1127
30. Nakashima Y, Tohmatsu T, Hattori H, Okano Y, Nozawa Y (1986) Inhibitory action of cyclic GMP on secretion, polyphosphoinositide hydrolysis and calcium mobilization in thrombin stimulated human platelets. Biochem Biophys Res Commun 135: 1099-1104
31. Siess W, Grunberg B, Luber K (1993) Functional relationship between cyclic AMP-dependent protein phosphorylation and platelet inhibition. Adv Exp Med Biol 344: 299-335
32. Ignarro LJ, Kadowitz PJ (1985) Pharmacological and physiological role of cGMP in vascular smooth muscle cell relaxation. Annu Rev Pharmacol Toxicol 25: 171-191
33. 2+ channels by cAMP and cGMP in vascular smooth muscle cells. Circ Res 73: 1128-1137
34. Yamagishi T, Yanagisawa T, Satoh K, Taira N (1994) Relaxant mechanisms of cyclic AMP-increasing agents in porcine coronary artery. Eur J Pharmacol 251: 253-262
35. Murad F (1996) Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest 78: 1-5
36. Gorman RR, Bunting S, Miller OV (1977) Modulation of human platelet adenylate cyclase by prostacyclin. Prostaglandins 13: 377-388
37. Tateson J, Moncada S, Vane JR (1977) Effects of prostacyclin on cyclic AMP concentrations in human platelets. Prostaglandins 13: 389-399
38. 1/prostacyclin receptor of human blood platelets. J Biol Chem 262: 12685-12691
39. Van Calker P, Muller M, Hamprecht B (1979) Adenosine regulates via two different types of receptors the accumulation of cAMP in cultured brain cells. J Neurochem 33: 999-1005
40. Kerry K, Scrutton MC (1983) Platelet β-receptors. Br J Pharmacol 79: 681-691
41. Sibley DR, Monsma FJ (1992) Molecular biology of dopamine receptors. Trends Pharmacol Sci 13: 61-69
42. Seamon KB, Daly JW (1983) Forskolin, cyclic AMP and cellular physiology. Trend Pharmacol Sci 4: 120-132
43. 2-adrenergic inhibition of adenylyl cyclase in platelet membranes: in situ identification with Gα C-terminal antibodies. Proc Natl Acad Sci USA 86: 7809-7813
44. 2 and prostacyclin. Pharmacol Rev 30: 293-331
45. Mustard JF, Kinlough-Rathbone RJ, Packham MA (1987) Vessel wall and thrombosis. In: Colman RW, Hirsch J, Marder VJ, Salzman E (eds) Hemostasis and Thrombosis. JB Lippincott Co, Philadelphia, pp 1073-1088
46. Waldman SA, Murad F (1987) Cyclic GMP synthesis and function. Pharmacol Rev 39: 163-196
47. Palmer RMJ, Ashton DS, Moncada S (1988) Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333: 664-666
48. Palmer RMJ, Ferridge AG, Moncada S (1987) Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (Lond) 327: 524-526
49. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ (1981) Evidence for the inhibitory role of guanosine-3′,5′-cyclic monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 57: 946-955
50. Moncada S, Palmer RMJ, Higgs EA (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-141
51. de Graaf JC, Banga JD, Moncada S, Palmer RMJ, de Groot PG, Sixma JJ (1992) Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 85: 2284-2290
52. Stamler J, Mendelsohn ME, Amarante P, et al. (1989) N-Acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ Res 65: 789-795
53. Michelson AD, Benoit SE, Furman MI, et al. (1996) Effects of endothelium-derived relaxing factor/nitric oxide on platelet surface glycoproteins. Am J Physiol 270:H1640-H1648
54. Bredt DS, Snyder SH (1990) Isolation of nitric oxide synthase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 87: 682-685
55. Radomski MW, Palmer RMJ, Moncada S (1990) An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 87: 5193-5197
56. Radomski MW, Palmer RMJ, Moncada S (1990) Characterization of the L-arginine: nitric oxide pathway in human platelets. Br J Pharmacol 101: 325-328
57. Sase K, Michel T (1995) Expression of constitutive endothelial nitric oxide synthase in human blood platelets. Life Sci 57: 2049-2055
58. Chen LY, Metha JL (1996) Variable effects of L-arginine analogs on L-arginine-nitric oxide pathway in human neutrophils and platelets may relate to different nitric oxide synthase isoforms. J Pharmacol Exp Ther 276: 253-257
59. Muragandam A, Mutus B (1994) Isolation of nitric oxide synthase from human platelets. Biochim Biophys Acta 1200: 1-6
60. Malinski T, Radomski MW, Taha Z, Moncada S (1993) Direct electrochemical measurement of nitric oxide released from human platelets. Biochem Biophys Res Commun 194: 960-965
61. Zhou Q, Hellermann GR, Solomonson LP (1995) Nitric oxide release from resting human platelets. Thromb Res 77: 87-96
62. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF Jr, Michelson AD (1997) Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 100: 350-356
63. Palmer RMJ, Rees DD, Ashton DS, Moncada S (1988) L-Arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun 153: 1251-1256
64. Griscavage JM, Fukuto JM, Komori Y, Ignarro LJ (1994) Nitric oxide inhibits neuronal nitric oxide synthase by interacting with the heme prosthetic group. J Biol Chem 269: 21644-21649
65. Bodzenta-Lukaszyke A, Gbryelewicz A, Lukaszyk A, Bielawiec M, Konturek JW, Domschke W (1994) Nitric oxide synthase inhibition and platelet function. Thromb Res 75: 667-672
66. Adams MR, Forsyth CJ, Jessup W, Robinson J, Celermajer DS (1995) Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young man. J Am Coll Cardiol 26: 1054-1061
67. Radomski MW, Palmer RMJ, Moncada S (1987) The antiaggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 92: 639-646
68. Macdonald PS, Read MA, Dusting GJ (1988) Synergistic inhibition of platelet aggregation by endothelium-derived relaxing factor and prostacyclin. Thromb Res 49: 437-449
69. Anfossi G, Massucco P, Mularoni E, Cavalot F, Mattiello L, Trovati M (1993) Organic nitrates and compounds that increase intraplatelet cyclic guanosine monophosphate (cGMP) levels enhance the antiaggregating effects of the stable prostacyclin analogue Iloprost. Prostaglandins Leukot Essent Fatty Acids 49: 839-845
70. Salvemini D, Currie MG, Mollace V (1996) Nitric oxide-mediated cyclooxygenase activation: a key event in the antiplatelet effects of nitrovasodilators. J Clin Invest 97: 2562-2568
71. Sheth S, Colman R (1995) Regulatory and catalytic domains of platelet cAMP phosphodiesterases: targets for drug design. Semin Hematol 31: 110-119
72. Conti M, Nemoz G. Sette C, Vicini E (1995) Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr Rev 16: 370-389
73. Maurice DH, Haslam RJ (1990) Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 37: 671-681
74. Hajek A, Joist J, Baker RK, Jarrett L (1979) Demonstration and partial characterization of insulin receptors in human platelets. J Clin Invest 63: 1060-1065
75. Falcon C, Pfliegler G, Deckmyn H, Vermylen J (1988) The platelet insulin receptor: detection, partial characterization, and search for a function. Biochem Biophys Res Commun 157: 1190-1196
76. Lopez Aparicio P, Rascona A, Manganiello VC, Andersson KE, Belfrage P, Degerman E (1992) Insulin-induced phosphorylation and activation of cGMP-inhibited cAMP phosphodiesterase in human platelets. Biochem Biophys Res Commun 186: 517-523
77. Udvardy G, Pfliegler G, Rab K (1985) Platelet insulin receptor determination in non-insulin dependent diabetes mellitus. Experientia 41: 422-423
78. Trovati M, Anfossi G, Cavalot F, et al. (1986) Studies on mechanisms involved in hypoglycemia-induced platelet activation. Diabetes 35: 818-825
79. Trovati M, Anfossi G, Cavalot F, Massucco P, Mularoni E, Emanuelli G (1988) Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo. Diabetes 37: 780-786
80. Trovati M, Anfossi G, Mularoni E, Massucco P, Bosia A, Emanuelli G (1989) Insulin reduces platelet sensitivity to platelet activating factor in washed human platelets resuspended in a calcium-free medium. Diabetes, Nutrition & Metabolism 2: 151-153
81. Trovati M, Anfossi G, Cavalot F, Massucco P Mularoni E, Emanuelli G (1990) Physiological insulin concentrations reduce platelet sensitivity to adrenaline in vivo. In: Belfiore F, Molinatti GM, Reaven GM (eds) Tissue-specific metabolic alterations in diabetes. Frontiers in diabetes, vol 10. Karger, Basel, pp 166-169
82. Trovati M, Massucco P, Mattiello L, Mularoni E, Cavalot F, Anfossi G (1994) Insulin increases guanosine-3′,5′-cyclic monophosphate in human platelets: a mechanism involved in the insulin anti-aggregating effect. Diabetes 43: 1015-1019
83. Trovati M, Mularoni E, Burzacca S et al. (1995) Impaired insulin-induced platelet anti-aggregating effect in obesity and in obese non-insulin-dependent diabetes mellitus. Diabetes 44: 1318-1322
84. Touyz RM, Schiffrin EL (1994) Blunted inhibition by insulin of agonist-stimulated calcium, pH and aggregatory responses in platelets from hypertensive patients. J Hypertens 12: 1255-1263
85. Hiramatsu K, Nozaki H, Arimori A (1987) Reduction of platelet aggregation induced by euglycaemic insulin clamp. Diabetologia 30: 310-313
86. Kahn NN, Bauman WA, Sinha AK (1993) Inhibition of platelet aggregation and the stimulation of prostacyclin synthesis by insulin in humans. Am J Physiol 265: H2160-H2167
87. 1 binding to human blood platelet membrane by insulin and the activation of adenylate cyclase. J Biol Chem 265: 4976-4981
88. 2 adrenergic receptor numbers in platelets by insulin. Biochim Biophys Acta 1134: 292-296
89. Dutta-Roy AK (1994) Insulin-mediated processes in platelets, erythrocytes and monocytes/macrophages: effects of essential fatty acid metabolism. Prostaglandins, Leukot Essent Fatty Acids 51: 385-399
90. Murer EH, Gyda MA, Martinez NJ (1994) Insulin increases the aggregation response of human platelets to ADP. Thromb Res 73: 69-74
91. Anfossi G, Massucco P, Mattiello L, et al. (1996) Insulin exerts opposite effects on platelet function at physiological and supraphysiological concentrations. Thromb Res 82: 57-68
92. Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37: 1595-1607
93. De Fronzo RA, Ferrannini E (1991) Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173-194
94. Standley PR, Zhang F, Ram JL, Zemel MB, Sowers JR (1991) Insulin attenuates vasopressin-induced calcium transients and voltage-dependent calcium current (a voltage-dependent calcium response) in rat vascular smooth muscle cells. J Clin Invest 88: 1230-1236
95. Wambach GK, Liu K (1992) Insulin attenuates vasoconstriction by noradrenaline, serotonin and potassium chloride in rat mesenteric arterioles. Clin Exp Hypertens A14: 733-740
96. Hori MT, Fittingoff M, Tuck ML (1992) Mechanism of insulin attenuation of calcium mobilization in cultured vascular smooth muscle cells. Hypertension 20: 397-398
97. 2+ transport in cultured vascular smooth muscle cells from spontaneously hypertensive rats. Am J Hypertens 5: 892-895
98. Standley PR, Ram JL, Sowers JR (1993) Insulin attenuation of vascular smooth muscle calcium responses in Zucker lean and obese rats. Endocrinology 133: 1693-1699
99. Kahn AM, Seidel CL, Allen JC, O'Neil RG, Shelat H, Song T (1993) Insulin reduces contractions and intracellular calcium concentration in vascular smooth muscle. Hypertension 22: 735-742
100. Kim YC, Zemel MB (1993) Insulin increases vascular smooth muscle recovery from intracellular calcium loads. Hypertension 22: 74-77
101. Ram JL, Fares MA, Standley PR, Sowers JR (1993) Insulin inhibits vasopressin-eliciled contraction of vascular smooth muscle cells. Journal of Vascular Medicine and Biology 4: 250-255
102. Saito F, Hori MT, Fittingoff M, Hino T, Tuck ML (1993) Insulin attenuates agonist-mediated calcium mobilization in cultured rat vascular smooth muscle cells. J Clin Invest 92: 1161-1167
103. Touyz RM, Tolloczko B, Schiffrin EL (1994) Insulin attenuates agonist-evoked calcium transients in vascular smooth muscle cells. Hypertension 23 [Suppl. I] I:23-28
104. 2+ influx in vascular smooth muscle. Circulation 90: 384-390
105. Inishi Y, Okuda T, Arakawa T, Kurokawa K (1994) Insulin attenuates intracellular calcium responses and cell contraction caused by vasoactive agents. Kidney Int 45: 1318-1325
106. 2+ level and contraction in the rat aorta: endothelium - dependent and independent mechanisms. Circ. Res. 77: 673-678
107. 2+ store in porcine coronary artery smooth muscle. Diabetes 46: 876-880
108. Somlyo AV, Bond M, Somlyo AP, Scarpa A (1985) Inositol trisphosphate-induced calcium release and contraction in vascular smooth muscle. Proc Natl Acad Sci USA 82: 5231-5235
109. Chadwick CC, Saito A, Fleischer S (1990) Isolation and characterization of the inositoltrisphosphate receptor from smooth muscle. Proc Natl Acad Sci USA 87: 2132-2136
110. +-ATPase gene expression by insulin in vascular smooth muscle cells. Am J Hypertens 6: 626-629
111. 2+ influx. J Nutr 125: 1732S-1737S
112. Sowers JR (1996) Effects of insulin and IGF-1 on vascular smooth muscle glucose and cation metabolism. Diabetes 45: 47-51
113. 2+ transport. Nature 349: 567-568
114. Moore RD (1983) Effects of insulin upon ion transport. Biochim Biophys Acta 737: 1-49
115. +-ATPase: mechanisms underlying rapid and sustained changes in pump activity. Am J Physiol 269: C295-C311
116. + exchange by insulin in the human forearm. Am J Physiol 255:E953-E958
117. 2+ store size. J Hypertens 11: 1089-1095
118. +-ATPase in thyrotoxic periodic paralysis. Clin Endocrinol (Oxf) 41: 213-216
119. Sowers JR (1997) Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 29: 691-699
120. Erne P, Bolli P, Burgisser E, Buhler ER (1984) Correlation of platelet calcium with blood pressure. Effects of anti-hypertensive therapy. N Engl J Med 310: 1084-1088
121. Buhler FR, Resink TJ (1988) Platelet membrane and calcium control abnormalities in essential hypertension. Am J Hypertens 1: 42-46
122. Oshima T, Young EW, Bukoski RD, McCarron DA (1990) Abnormal calcium handling by platelets of spontaneously hypertensive rats. Hypertension 15: 606-611
123. 2+ in hypertensive rats. Hypertension 18: 758-762
124. Ishii H, Nmeda F, Hashimoto T, Nawata H (1991) Increased intracellular calcium mobilization in platelets from pateints with type II (non-insulin-dependent) diabetes mellitus. Diabetologia 34: 332-336
125. Ishida-Kainouchi M, Matsuura H, Ishida T, Kajiyama G, Oshima T (1993) Platelet calcium handling in spontaneously hypertensive rats and in three strains of normolensive rats. J Hypertens 11: 509-514
126. Standley PR, Ali S, Bapna C, Sowers JR (1993) Increased platelet cytosolic calcium responses to low density lipoprotein in type II diabetes with and without hypertension. Am J Hypertens 6: 938-943
127. Levy J, Gavin JR, Sowers JR (1994) Diabetes mellitus: a disease of abnormal cellular calcium metabolism? Am J Med 96: 260-273
128. Takaya J, Iwamoto Y, Higashino H, Kino M, Kobayashi T, Kobayashi Y (1997) Altered intracellular calcium and phorhol 12,13-dibutyratc binding to intact platelets in young obese subjects. J Lab Clin Med 129: 245-250
129. 2+ channel blockers is associated with increased platelet sensitivity to insulin. Am J Hypertens 8: 1214-1221
130. Baldi S, Natali A, Buzzigoli G, Galvan AO, Sironi AM, Ferrannini E (1996) In vitro effect of insulin on intracellular calcium concentrations: relation to insulin resistance. Metabolism 45: 1402-1407
131. 2+ is altered in vascular smooth muscle cells of SHR. Hypertension 23: 931-935
132. Sowers JR, Standley PR, Ram JL, Jacober S (1993) Hyperinsulinemia, insulin resistance, and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis. Am J Hypertens 6: 260S-270S
133. Standley PR, Bakir MH, Sowers JR (1993) Vascular insulin abnormalities, hypertension and accelerated atherosclerosis. Am J Kidney Dis 21: 39-46
134. Epstein M, Sowers JR (1992) Diabetes mellitus and hypertension. Hypertension 19: 403-418
135. Ram JL, Standley PR, Sowers JR (1993) Hypertension, insulin function, and calcium. In: Draznin B, Eckel RH (eds) Diabetes and Atherosclerosis: molecular basis and clinical aspects. Elsevier, New York, pp 291-305
136. Draznin B, Sussman KE, Eckel RH, et al. (1988) Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia. J Clin Invest 28: 1848-1852
137. Levy J, Zemel MB, Sowers JR (1989) Role of cellular calcium metabolism in abnormal glucose metabolism and diabetic hypertension. Am J Med 87 (suppl 6A):7S-16S
138. Resnick LM, Gupta RK, Bhargava KK et al. (1991) Cellular ions in hypertension, diabetes and obesity. A nuclear magnetic resonance spectroscopic study. Hypertension 17: 951-957
139. Illiano G, Cuatrecasas P (1972) Modulation of adenylate cyclase activity in liver and fat cell membranes by insulin. Science 1975: 906-908
140. Senft G, Schultz G, Munske K, Hoffman M (1968) Influence of insulin on cyclic 3′,5′ phosphodiesterase activity in liver, skeletal muscle, adipose tissue and kidney. Diabetologia 4: 322-329
141. Degerman E, Smith CJ, Tornqvist H, Vasta V, Belfrage P, Manganiello VC (1990) Evidence that insulin and isoprenaline activate the c-GMP inhibited low-Km cAMP phosphodiesterase in rat fat cells by phosphorylation. Proc Natl Acad Sci USA 87: 533-53
142. Butcher RW, Baird CE, Sutherland EW (1968) Effects of antilipolytic substances on adenosine 3′,5′ monophosphate levels in isolated fat cells. J Biol Chem 243: 1705-1712
143. Illiano G, Tell GPE, Siegel MI, Cuatrecasas P (1973) Guanosine 3′:5′-cyclic monophosphate and the action of insulin and acethylcholine. Proc Nat Acad Sci USA 70: 2443-2447
144. Vesely DL, Castro A, Levey GS (1977) Decreased rat hepatic guanylate cyclase activity in streptozotocin-induced diabetes mellitus. Diabetes 26: 308-313
145. Lopez-Aparicio P, Belfrage P, Manganiello VC, Kono T, Degerman E (1993) Stimulation by insulin of a serine kinase in human platelets that phosphorylates and activates the cGMP-inhibited cAMP phosphodiesterase. Biochem Biophys Res Commun 193: 1137-1144
146. Trovati M, Massucco P, Mattiello L et al. (1996) The insulin-induced increase of guanosine-3′,5′-cyclic monophosphate in human platelets is mediated by nitric oxide. Diabetes 45: 768-770
147. Trovati M, Anfossi G, Massucco P et al. (1997) Insulin stimulates nitric oxide synthesis in human platelets, and, through nitric oxide, increases platelet concentrations of both guanosine-3′-5′-cyclic monophosphate and adenosine-3′-5′-cyclic monophosphate. Diabetes 46: 742-749
148. Zeng G, Quon MJ (1996) Insulin-stimulated production of nitric oxide is inhibited by wormannin. Direct measurement in vascular enothelial cells. J Clin Invest 98: 894-898
149. Axelsson KL, Andersson RGG (1983) Tolerance towards nitroglycerin, induced in vivo, is correlated to a cGMP response and an alteration in cGMP turnover. Eur J Pharmacol 88: 71-79
150. Waldman SA, Rapoport RM, Murad F (1987) Desensitization to nitroglycerin in vascular smooth muscle from rat and human. Biochem Pharmacol 35: 3525-3531
151. Arnold WP, Mittal CK, Katsuki S, Murad F (1977) Nitric oxide activates guanylate cyclase and increases guanosine 3′,5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 74: 3203-3207
152. Lewicki JA, Brandwein HJ, Mittal CK, Arnold WP. Murad F (1982) Properties of purified soluble guanylate cyclase activated by nitric oxide and sodium nitroprusside. Journal of Cyclic Nucleotide Research 8: 17-25
153. Anfossi G, Massucco P, Mularoni E, Cavalot F, Mattiello L, Trovati M (1994) Effects of forskolin and organic nitrate on aggregation and intracellular cyclic nucleotide content in human platelets. Gen Pharmacol 25: 1093-1100
154. Mittal KC, Murad F (1977) Formation of adenosine 3′,5′-monophosphate by preparations of guanylate cyclase from rat liver and other tissues. J Biol Chem 252: 3136-3140
155. Trovati M, Massucco P, Mattiello L et al. (1995) Insulin increases cyclic nucleotide content in human vascular smooth muscle cells: a mechanism potentially involved in insulin-induced modulation of vascular tone. Diabetologia 38: 936-941
156. Trovati M, Massucco P, Mattiello L et al. (1996) Studies on the insulin influence on cyclic adenosine monophosphate in human vascular smooth muscle cells: dependence on cyclic guanosine monophosphate and modulation of catecholamine effects. Diabetologia 39: 1156-1164
157. Massucco P, Anfossi G, Mattiello L et al. (1998) Insulin acutely increases cyclic nucleotide concentrations in human vascular smooth muscle cells by stimulating nitric oxide synthesis. Eur J Clin Invest 28 (Suppl. 1): A 28 (Abstract)
158. Michel T, Li GK, Busconi L (1993) Phosphorylation and subcellular translocation of endothelial nitric oxide synthase. Proc Natl Acad Sci USA 90: 6252-6256
159. Anfossi G, Mularoni E, Burzacca et al. (1998) Platelet resistance to nitrates in obesity and obese NIDDM and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care 21: 121-126
160. Woods JD, Edwards JS, Ritter JM (1993) Inhibition by nitroprusside of platelet calcium mobilization: evidence for reduced sensitivity to nitric oxide in essential hypertension. J Hypertens 11: 1369-1373
161. +-ATPase activity by nitric oxide: a cGMP-independent effects. A J Phvsiol 266:H2146-H2151
162. +-ATPase activity in rabbit aorta by hyperelycemia: possible role of endothelium-derived nitric oxide. J Clin Invest 90: 727-732
163. Tare M, Parkington HA, Coleman HA, Nerld TO, Dusting GF (1990) Hyperpolarization and relaxation of arterial smooth muscle caused by nitric oxide derived from endothelium. Nature 346: 69-71
164. Bolotina VM, Najibl S, Palacino JJ, Pagano PJ, Cohen RA (1994) Nitric oxide directly activates calcium dependent potassium channels in vascular smooth muscle. Nature 368: 850-853
165. 1/prostacyclin and insulin in human erythrocytes and platelets. Life Sci 49: 1129-1139
166. 2 receptor number and ADP ribosylation of G-alpha by insulin in platelets. FASEB J 7: 1148
167. Ishida M, Ishida T, Ono N et al. (1996) Effects of insulin on calcium metabolism and platelet aggregation. Hypertension 28: 209-212
168. Jap TS, Kwok CF, Wong MC, Chiang H (1994) The effects of in vitro and in vivo exposure to insulin upon prostaglandin E, stimulation of platelet adenylate cyclase activity in healthy subjects. Diabetes Research 27(1):39-46
169. Smitherman TC, Halam M, Woo J, Willerson JT, Frenkel EP (1981) Elevated thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: direct evidence of enhanced platelet reactivity in vivo. Am J Cardiol 48: 395-402
170. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM (1989) Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 80: 198-205
171. Metha P, Metha J (1980) Platelet function studies in coronary heart disease: VIII. Decreased platelet sensitivity to prostacyclin in patients with myocardial ischemia. Thromb Res 18: 273-277
172. Neri Serneri GG, Fortini A, Lombardi A, Modesti PA, Abbate R, Gensini GF (1984) Reduction in prostacyclin platelet receptors in active spontaneous angina. Lancet 2: 838-841
173. 2 receptor activity of human blood platelets in acute ischemic heart disease. Circ Res 66: 932-940
174. 2 receptor activity of platelets in acute ischemic heart disease. Circ Res 68: 245-254
175. 2 and synthesis of prostacyclin by insulin in unstable angina pectoris and in acute myocardial in-farction. Am J Cardiol 70: 582-586
176. Kahn NN, Bauman WA, Sinha AK (1994) Transient decrease of binding of insulin to platelets in acute ischemic heart disease. Am J Med Sci 307: 21-26
177. Kahn NN, Bauman WA, Sinha AK (1996) Loss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandin-induced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury. Proc Nat Acad Sci USA 93: 245-249
178. Farias RN (1987) Insulin-membrane interactions and membrane fluidity changes. Biochim Biophys Acta 906: 459-468
179. Hwang DL, Yen CF, Nadler J (1993) Insulin increases intracellular magnesium transport in human platelets. J Clin Endocrinol Metab 76: 549-553
180. Hwang D, Yen C, Nadler J (1992) Effect of extracellular magnesium on platelet activation and intracellular calcium mobilization. Am J Hypertens 5: 700-706
181. Resnick LM, Altura BT, Gupta RK, Laragh JH, Alderman MH, Altura BM (1993) Intracellular and extracellular magnesium depletion in type 2 (non-insulin dependent) diabetes mellitus. Diabetologia 36: 767-770
182. Erickson LA, Ginsberg MH, Loskutoff DJ (1984) Detection and partial characlerization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 74: 1465-1472
183. Jeanneau C, Sultan Y (1988) Tissue plasminogen activator in human megakariocytes and platelets: immunoblotting and zymographic analysis. Thromb Haemost 59: 529-534
184. Park S, Harker L, Marzee VM, Levine EG (1989) Demonstration of single chain-type plasminogen activator in platelet membrane. Blood 73: 1421-1425
185. Kahn NN, Bauman WA, Sinha AK (1995) Insulin-induced release of plasminogen activator from human blood platelets. Am J Physiol 268:H117-H124
186. Jokil R, Laimins M, Klein RL, Lyons TJ, Lopes-Virella MF, Colwell JA (1994) Platelet plasminogen activator inhibitor 1 in platelets with type II diabetes. Diabetes Care 17: 818-823
187. Pandolfi A, Iacoviello L, Capani F, Vitacolonna E, Donati MB, Consoli A (1996) Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth cells in culture. Diabetologia 39: 1425-1431
188. Stout RW (1990) Insulin and atheroma - a 20 year perspective. Diabetes Care 13: 631-654
189. Cavalot F, Russo I, Mattiello L et al. (1997) Influence of protamine on adhesion, chemotaxis and proliferation of human vascular smooth muscle cells. Diabetologia 40: 67-75
190. Colwell JA, Gisinger C, Klein R (1992) Altered platelet function in diabetes mellitus: effect of glycemic regulation and antiplatelet agents. In: Ruderman N, Williamson J, Brownlee M (eds) Hyperglycemia, diabetes, and vascular diseases. Oxford University Press, New York, Oxford; pp 30-47